CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
· manilatimes.net
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB)
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB)
Neflamapimod awarded Innovation Pa...